LDLR Recombinant Rabbit Monoclonal Antibody (SJ0197), Invitrogen™

Description

Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire. For Flow cytometry, cells should be fixed and permeabilized before staining.

The low density lipoprotein receptor (LDL-R) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in the LDL-R gene cause the autosomal dominant disorder, familial hypercholesterolemia. Along with SCARB1, CLDN1, and the tetraspanin superfamily member CD81, LDL-R has been reported to be an entry factor for the Hepatitis C virus. At least three isoforms of LDL-R are known to exist.